CVR number 25917073
Industry 86.9020 Other human health activities

FYSIOTERAPI NORDVEST ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.3% 1.4% 2.6% 3.3% 2.1%  
Credit score (0-100)  81 80 61 53 66  
Credit rating  A A BBB BBB BBB  
Credit limit (kDKK)  26.3 22.5 0.0 0.0 0.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Gross profit  4,741 4,955 4,881 6,215 6,344  
EBITDA  910 746 399 344 881  
EBIT  781 625 283 233 799  
Pre-tax profit (PTP)  766.6 647.6 304.8 250.1 750.4  
Net earnings  595.4 503.7 236.0 192.6 585.1  
Pre-tax profit without non-rec. items  767 648 305 250 750  
 
See the entire income statement

Balance sheet (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Tangible assets total  752 630 514 404 321  
Shareholders equity total  1,160 1,114 900 592 877  
Interest-bearing liabilities  981 915 1,176 1,506 1,617  
Balance sheet total (assets)  2,980 2,765 3,019 3,012 3,420  
Net Debt  974 901 1,165 1,505 1,596  
 
See the entire balance sheet

Volume 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  4,741 4,955 4,881 6,215 6,344  
Gross profit growth  8.1% 4.5% -1.5% 27.3% 2.1%  
Employees  9 10 9 13 13  
Employee growth %  0.0% 11.1% -10.0% 44.4% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,980 2,765 3,019 3,012 3,420  
Balance sheet change%  13.4% -7.2% 9.2% -0.2% 13.5%  
Added value  781.0 625.2 283.3 233.2 798.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -258 -242 -232 -221 -165  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  16.5% 12.6% 5.8% 3.8% 12.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  28.8% 23.8% 11.8% 9.5% 25.4%  
ROI %  38.6% 31.6% 15.8% 13.2% 34.5%  
ROE %  60.3% 44.3% 23.4% 25.8% 79.6%  

Solidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  38.9% 40.3% 29.8% 19.7% 25.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  107.1% 120.7% 291.7% 438.0% 181.1%  
Gearing %  84.6% 82.2% 130.7% 254.4% 184.3%  
Net interest  0 0 0 0 0  
Financing costs %  3.8% 3.7% 3.4% 2.8% 4.2%  

Liquidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  1.1 1.2 1.1 1.0 1.1  
Current Ratio  1.1 1.2 1.1 1.0 1.1  
Cash and cash equivalent  6.5 14.2 11.1 1.4 21.5  

Capital use efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  146.5 252.5 172.1 -40.9 184.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  87 63 31 18 61  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  101 75 44 26 68  
EBIT / employee  87 63 31 18 61  
Net earnings / employee  66 50 26 15 45